[RENAL TUBULAR DYSGENESIS SECONDARY TO MUTATIONS IN GENES ENCODING THE RENIN-ANGIOTENSIN SYSTEM].


Journal

Harefuah
ISSN: 0017-7768
Titre abrégé: Harefuah
Pays: Israel
ID NLM: 0034351

Informations de publication

Date de publication:
Dec 2021
Historique:
entrez: 27 12 2021
pubmed: 28 12 2021
medline: 29 12 2021
Statut: ppublish

Résumé

Autosomal recessive renal tubular dysgenesis (RTD;OMIM: 267430) is a rare kidney disease secondary to mutations in genes encoding the renin-angiotensin system which have a role in renal tissue development during fetal life and in the maintenance of blood pressure and electrolyte balance. The disease is characterized by oligohydramnios, prematurity, neonatal renal failure, hypotension and abnormalities in cranial bone development. Nearly all affected individuals die either in-utero or within the first few days of life, although a few long term survivors were reported during the last decade. We describe the management of 5 newborns diagnosed with RTD in pregnancy who survived the neonatal period, four of them belong to an extended Bedouin family. In 4/5 patients we identified a mutation in angiotensin converting enzyme (ACE) gene. Variable presentation was noticed in the patients, starting with peritoneal dialysis and extreme low blood pressure treated with vasopressors and plasma infusions and ending with no symptoms. Currently, the patients are 5-20 years old with variable stages of chronic kidney disease. In conclusion, the spectrum of RTD is wider than previously reported. Prompt diagnosis is necessary for optimal decision-making by families and physicians. Intensive treatment of low blood pressure in the postnatal period is critical for their survival and better prognosis.

Identifiants

pubmed: 34957720

Substances chimiques

ACE protein, human EC 3.4.15.1
Peptidyl-Dipeptidase A EC 3.4.15.1

Types de publication

Case Reports Journal Article

Langues

heb

Sous-ensembles de citation

IM

Pagination

822-826

Auteurs

Ruth Schreiber (R)

Saban Pediatric Medical Center, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer Sheva, Israel.

Vadim Dolgin (V)

The Morris Kahn Laboratory of Human Genetics, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Daniel Landau (D)

Schneider Children's Medical Center, Tel Aviv University, Petah Tikva, Israel.

Evgenia Gurevich (E)

Schneider Children's Medical Center, Tel Aviv University, Petah Tikva, Israel.

Hanna Shalev (H)

Saban Pediatric Medical Center, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer Sheva, Israel.

Michael Geylis (M)

Saban Pediatric Medical Center, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer Sheva, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH